- Home
- INCY vs CLX Comparison
INCY vs CLX Comparison
Compare INCY & CLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | CLX |
|---|---|---|
| Founded | 1991 | 1913 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 14.9B |
| IPO Year | 1994 | 1994 |
Fundamental Metrics
Financial Performance| Metric | INCY | CLX |
|---|---|---|
| Price | $100.35 | $126.89 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 12 |
| Target Price | $100.63 | ★ $121.08 |
| AVG Volume (30 Days) | 1.7M | ★ 2.2M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 4.01% |
| EPS Growth | ★ 4173.33 | 189.78 |
| EPS | ★ 6.41 | 1.93 |
| Revenue | $3,394,635,000.00 | ★ $6,124,000,000.00 |
| Revenue This Year | $11.02 | N/A |
| Revenue Next Year | $9.97 | $7.17 |
| P/E Ratio | ★ $15.81 | $64.04 |
| Revenue Growth | ★ 13.67 | N/A |
| 52 Week Low | $53.56 | $96.66 |
| 52 Week High | $112.29 | $159.04 |
Technical Indicators
Market Signals| Indicator | INCY | CLX |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 72.16 |
| Support Level | $97.99 | $117.56 |
| Resistance Level | $109.49 | $132.03 |
| Average True Range (ATR) | 3.58 | 3.59 |
| MACD | -0.26 | 0.17 |
| Stochastic Oscillator | 24.61 | 96.17 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About CLX Clorox Company (The)
Since its inception more than 100 years ago, Clorox has expanded to operate in a variety of consumer product categories, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water filtration products, and natural personal care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. More than 80% of Clorox's sales come from its home turf.